title: Clinical observation of Yinzhihuang Oral Liquid on prevention of the premature infantile jaundice.
abstract: OBJECTIVE
  To observe the clinical efficacy of Yinzhihuang Oral Liquid (YOL) to prevent the premature infantile jaundice.
  
  
  METHODS
  After excluded hemolytic, suffocation, infection, and the very low birth weight, 242 cases of premature infants were randomly assigned to two groups, the treatment group and the control group. Both groups were taken conventional procedures, such as warmth, feeding, and blood glucose monitoring, and the treated group was administered YOL 5 mL each time, twice daily additionally, and the control group without any treatment. The percutaneous bilirubin and blood cells were observed every day.
  
  
  RESULTS
  Compared the two groups, the jaundice indices were more significantly different at 24-48 h, 48-72 h, and more than 72 h (P<0.05), but not statistically different at 0-24 h (P>0.05). Hemoglobin, reticulocyte, platelets, and leucocyte were not significantly different between the two groups (P>0.05).
  
  
  CONCLUSIONS
  YOL as an early intervention has positive significance to decrease the incidence of pathological jaundice in the premature infants, and no significant impact on the blood cells.
authors.affiliation: Department of Obstetrics and Gynecology, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China. bingmchen@sina.com
authors.forename: Sheng-ping
authors.initials: SP
authors.lastname: Chen
authors.forename: Li-li
authors.initials: LL
authors.lastname: Tian
authors.forename: Feng-ling
authors.initials: FL
authors.lastname: Liu
mesh_terms: D000284:Administration, Oral; D001663:Bilirubin / Q000378:metabolism; D001773:Blood Cells / Q000187:drug effects / Q000378:metabolism; D004304:Dosage Forms; D004334:Drug Administration Schedule; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000517:prevention & control*; D007567:Jaundice, Neonatal / Q000517:prevention & control*; D008297:Male; D012867:Skin / Q000187:drug effects / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D004304:Dosage Forms; D004365:Drugs, Chinese Herbal; C070600:yin zhi huang; D001663:Bilirubin
references.citation: Clin Perinatol. 2000 Mar;27(1):171-9, vii
references.pmid: 10690570